Genome-wide Mendelian Randomization Identifies Potential Drug **Targets for Dorsopathies**

- Yu Cui 1,2,† , Jiarui Guo 1,2,† , Yuanxi Lu 1,2,† , Mengting Hu 1,2 , He Zhou 1,2 , Wancong Zhang 2,3,4,* , Shijie Tang 2,3,4,* 1
- 2
- 3 †These authors contributed equally to this work and share first authorship
- ¹Shantou University Medical College, Shantou, Guangdong 515041, China 5
- 6 ²Department of Plastic Surgery and Burns Center, Second Affiliated Hospital, Shantou University
- 7 Medical College, Shantou, Guangdong 515051, China
- 8 ³Plastic Surgery Institute of Shantou University Medical College, Shantou, Guangdong 515051,
- 9 China

- 10 ⁴Shantou Plastic surgery Clinical Research Center, Shantou, Guangdong 515051, China
- 11 * Correspondence:
- Wancong Zhang, Shijie Tang 12
- 13 Martine2007@sina.com, sjtang3@stu.edu.cn
- 14 Keywords: Mendelian randomization, Genetics, Drug target, Dorsopathies, Colocalization
- 15 analysis, Genome-wide association studies, Expression quantitative trait locus.
- 16 **Abstract**
- 17 **Background** Dorsopathies are a group of musculoskeletal disorders affecting the spinal column and
- related structures, contributing significantly to global disability rates and healthcare costs. Despite 18
- 19 their prevalence, the genetic and biological mechanisms underlying dorsopathies are not fully
- 20 understood.
- 21 Method Summary-data-based Mendelian Randomization (SMR) and colocalization analysis were
- 22 employed, using data from genome-wide association studies (GWAS) and cis-expression quantitative
- 23 trait loci (cis-eQTLs) databases. Genes with a colocalization posterior probability (PP.H4) above 0.7
- in SMR results were selected for additional analysis. These selected genes underwent MR analysis to 24
- examine possible causal connections with dorsopathies, and sensitivity analyses were carried out to 25
- 26 ensure robustness. Additionally, two transcriptome-wide association studies (TWAS) were utilized to
- 27 confirm and screen for potential drug targets.
- 28 **Result** We identified four essential genes linked to dorsopathies: *NLRC4*, *CGREF1*, *KHK*, and
- 29 RNF212. Mendelian randomization (MR) analysis revealed a potential causal link between these
- 30 genes and dorsopathies. Elevated transcription levels of NLRC4, CGREF1, and KHK correlated with
- 31 reduced dorsopathies risk, while increased levels of RNF212 were associated with heightened risk of
- dorsopathies. Regarding methylation sites, an increase in cg04686953 fully mediated the decreased 32
- 33 risk of dorsopathies by RNF212. Similarly, the risk effect of cg26638505 and cg18948125 was
- entirely mediated by NLRC4, while CGREF1 predominantly mediated the risk-increasing effect of 34
- 35 cg06112415 and the decrease effect of cg22740783.

- 36 Conclusion Dorsopathies were associated with four pivotal genes: NLRC4, CGREF1, KHK, and
- 37 RNF212. Methylation analysis identified cg04686953 and cg22740783 as protective against
- dorsopathies risk, while cg26638505, cg18948125, and cg06112415 exhibited a risk-increasing
- 39 impact.

41

1 Introduction

- Dorsopathies encompass a broad spectrum of musculoskeletal issues that impact the spinal column
- and its related structures[1]. These conditions are prevalent among individuals across various age
- 44 groups and socioeconomic backgrounds, leading affected individuals to seek medical assistance.
- 45 They significantly contribute to the burden of illness, disability, and distress. Since 1990, there has
- been a notable rise in the prevalence of these disorders, rendering them one of the primary causes of
- 47 global disability-adjusted life years [2]. However, the pathogenic genes and biological mechanisms
- of the disease remain largely unknown. Research conducted on the general population has indicated a
- 49 potential link between certain dorsopathies and lifestyle choices including smoking [3], a higher body
- mass index[4,5], and lack of physical activity [6]. Additionally, these dorsopathies have been found
- 51 to coincide with various other health complications such as anxiety, depression, diabetes,
- 52 cardiovascular, respiratory, and gastrointestinal ailments[7,8]. Furthermore, specific dorsopathies like
- 53 osteopenia, osteomalacia, and tuberculosis can be influenced by factors such as diet, living
- environment, and psychological aspects. These particular disorders often occur alongside systemic
- comorbidities such as endocrine dysfunction and infection [8]. Relevant limitations in observational
- epidemiological studies include the potential for confounding, reverse causation, and diverse biases,
- 57 which hinder comprehensive understanding of disease pathogenesis and identification of treatment
- 58 targets.
- However, the utilization of Mendelian randomization (MR) techniques, which rely on the random
- allocation of genetic variations, allows for the simulation of randomized controlled trials and can
- effectively mitigate the impact of confounding variables. In relation to research on dorsopathies, this
- 62 implies a more precise evaluation of the causal association between drug targets and disease while
- excluding any factors that may potentially disrupt the findings [9]. MR utilizes genetic variants as
- 64 instrumental variables to assess the causal impact of an exposure on outcomes. This approach has
- been extensively utilized in other research studies related to diseases and has effectively facilitated
- the identification of potential therapeutic targets for diverse medical conditions.[10] However, there
- 67 is limited research on employing MR methods to explore potential drug targets for dorsopathies.
- 68 Therefore, to gain a deeper understanding of the pathogenesis of dorsopathies and identify more
- 69 effective treatment approaches, further MR studies are needed to evaluate the drug targets for
- dorsopathies. This will help eliminate factors that could interfere with the results and offer new
- 71 perspectives and methods for the treatment of dorsopathies. In theory, single nucleotide
- 72 polymorphisms (SNPs) are distributed randomly and not impacted by environmental factors, making
- them an ideal tool for establishing causality. MR is a type of instrumental variable analysis that
- primarily employs SNPs as genetic instruments to determine the causal impact of an exposure (in this
- 75 instance, circulatory proteins) on outcomes.[11]. Previous studies have successfully utilized MR to
- identify biomarkers and treatment targets for various diseases, such as a rtic aneurysms [12],
- 77 multiple sclerosis [13], and breast cancer [14].
- However, in previous studies, the use of MR To analyze drug targets for dorsopathies is very rare. To
- address this research gap, our study focuses on utilizing genes as factors of exposure in drug target

- 80 research, investigating the role of genes in dorsopathies development and their potential as viable
- drug targets. Genes have stable genetic characteristics, and they are unaffected by environmental
- factors, allowing for a more accurate assessment of the causal relationship between genes and
- dorsopathies [15]. By exploring dorsopathies' potential drug targets through genes as the exposure
- 84 factor, we aim to offer new perspectives and methods for the treatment and prevention of
- 85 dorsopathies.
- 86 To investigate potential pathogenic genes related to dorsopathies, we employed a comprehensive
- 87 analytical approach including summary-data-based Mendelian randomization (SMR) analysis,
- 88 colocalization analysis, genome-wide association study (GWAS), and transcriptome-wide association
- 89 study (TWAS). We utilized a meta-analysis dataset of cis-expression quantitative trait loci (cis-
- 90 eQTLs) from peripheral blood samples as exposure data, along with results from the extensive
- 91 FinnGen database. Following preliminary analysis, we identified candidate genes and established
- 92 causal inference using MR methods. Additionally, we conducted mediation analysis of gene-
- 93 mediated methylation sites to explore disease related methylation sites.

2 Method

94

95

107

108

2.1 Datasets

- 96 Summary-level data for the GWAS on dorsopathies were obtained from the FinnGen consortium,
- 97 comprising 117,411 cases and 294,770 controls. This dataset represents the most recent GWAS
- 98 findings and comprises the largest cohort of dorsopathies cases documented to date. The primary
- 99 objective of FinnGen is to accumulate and rigorously analyze genomic and national health register
- data from 500,000 Finnish individuals.[16] In the context of drug development studies, we prioritized
- 101 cis-eQTLs that were in closer proximity to the target gene. These cis-eQTLs used for SMR analyses
- were sourced from the eQTLGen Consortium [17] and the eQTL meta-analyses conducted on
- peripheral blood samples from a cohort of 31,684 individuals. For the TWAS analyses of eQTL data,
- we utilized the GTEx v8 European whole blood dataset. Given our specific emphasis on dorsopathies,
- we meticulously extracted comprehensive eQTL results exclusively from the whole blood samples
- within the GTEx dataset [18].

2.2 SMR analyses

- We conducted SMR and heterogeneity in dependent instruments (HEIDI) tests analyses on cis
- regions using the SMR software (version 1.03) [19]. The methodologies for SMR analyses are
- detailed in the original work. In brief, SMR analyses employs a well-established MR approach. This
- technique employs a SNP at a prominent cis-eQTL as an instrumental variable (IV). The summary-
- level eQTL data serve as the exposure variable, and the GWAS data for a specific trait serve as the
- outcome variable. The primary objective is to explore a potential causal or pleiotropic association,
- wherein the same causal variant influences both gene expression and the trait. It is crucial to
- acknowledge that the SMR method lacks the ability to distinguish between a causal association, in
- which gene expression causally influences the trait, and a pleiotropic association, in which the same
- 118 SNP affects both gene expression and the trait. This limitation arises because of the single
- instrumental variable (IV) in the MR method, which cannot differentiate between causality and
- pleiotropy. Nevertheless, the HEIDI test can make this distinction by discerning causality and
- pleiotropy from linkage. Linkage refers to cases in which two different SNPs in linkage
- disequilibrium (LD) independently influence gene expression and the trait. Although less biologically

- intriguing than causality and pleiotropy, the HEIDI test provides clarity in such scenarios. For the
- HEIDI test, a p-value below 0.05 was considered significant, suggesting that the observed association
- was attributable to linkage.

127

133

134

143

144

157

158

2.3 GWAS analyses

- Multimarker analyses of genomic annotation (MAGMA) employs a multiple regression model to
- assess the cumulative effect of multiple SNPs within a specific gene region (± 10 kb)[20]. The
- reference panel for calculating LD was derived from Phase 3 of the 1000 Genomes European
- population. Significance thresholds for GWAS analyses using both SMR and MAGMA were set at a
- false discovery rate (FDR) below 0.05, corrected using the Benjamini-Hochberg method.[21]

2.4 TWAS analyses

- We conducted validations to integrate dorsopathies GWAS and eQTL data of whole blood from
- 136 GTEx using the FUSION and UTMOST, widely utilized tools in prior TWAS investigations [22,23].
- 137 FUSION constructs predictive models using various penalized linear models, such as GBLUP,
- LASSO, Elastic Net, for the significant cis-heritability genes estimated from SNPs within 500 kb on
- either side of the gene boundary. Subsequently, it selects the optimal model based on the coefficient
- of determination (R2) calculated through a fivefold cross-validation. For UTMOST, we performed
- repeated 49 single-tissue association tests for each tissue. TWAS significance for both single-tissue
- analyses was determined with a Benjamini-Hochberg corrected FDR value below 0.05.

2.5 MR analyses

- In conducting the two-sample MR analyses [24], we utilized the TwoSampleMR R package. The
- utilization of the two-sample MR framework requires employing two distinct datasets. In this study,
- genetic instruments, specifically cis-eQTL, served as exposures, while GWAS were utilized to
- determine outcome traits. The MR methodology investigates the relationship between gene
- expression and diseases or traits by employing genetic variants associated with gene expression as
- instrumental variables (exposure) and GWAS for the outcome measures. Mendelian Randomization
- facilitates exploration into whether alterations in gene expression causally impact diseases or traits.
- For instruments represented by a single SNP, we employed the Wald ratio. In cases where
- instruments consisted of multiple SNPs, we implemented the inverse-variance-weighted MR
- approach. When selecting SNPs, the significance thresholds were defined as $P < 5 \times 10^{\circ}(-8)$ for
- genome-wide significance, with a linkage disequilibrium parameter (r^2) set to 0.1, and a genetic
- distance set to 10 MB.

2.6 Colocalization analyses

- 159 Conducted colocalization analyses using the coloc package in the R software environment (version
- 4.0.3). Colocalization analyses aims to assess the potential shared causality between SNPs associated
- with both gene expression and phenotype at a specific locus, thereby indicating the "colocalization"

- of these genetic signals. The analyses calculates posterior probabilities (PPs) for five hypotheses: H0
- denotes no association with either gene expression or phenotype; H1 signifies an association solely
- with gene expression; H2 indicates an association exclusively with the phenotype; H3 suggests an
- association with both gene expression and phenotype through independent SNPs; and H4 implies an
- association with both gene expression and phenotype through shared causal SNPs. A substantial PP
- 167 for H4 (PP.H4 above 0.70) strongly suggests the presence of shared causal variants influencing both
- gene expression and phenotype [25].

170

182

183

184

199

200

2.7 Methylation & Mediation analysis

- We hypothesize that methylation sites exert influence on the pathogenic risk of dorsopathies through
- three primary pathways: a) they indirectly modulate the pathogenic risk by influencing gene
- expression; b) the methylation sites themselves have a direct impact on the pathogenic risk of
- dorsopathies; and c) methylation sites may affect the pathogenic risk of dorsopathies by influencing
- other confounders. It is crucial to underscore that the overall impact of methylation on the pathogenic
- 176 risk of dorsopathies can be conceptualized as the combined action of these three pathways, expressed
- as T=a+b+c, where a denotes the indirect modulation of pathogenic risk by influencing gene
- expression, b denotes the direct effect of methylation sites on pathogenic risk, and c represents their
- influence on pathogenic risk through impacting confounding factors. Significance tests are conducted
- separately for T, x, y, and a. If all these parameters show significance, it can be inferred that the gene
- plays a role in the intermediate pathway, thereby substantiating the existence of the a) pathway.

3 Result

3.1 SMR analyses and colocalization for Preliminary Identifying Potential Genes

- In our initial analyses phase, we utilized the eQTLGen dataset for SMR analyses to pinpoint genes
- significantly linked to dorsopathies. Employing the FDR method set our p-value significance
- threshold. The eQTLGen dataset provided extensive data, yielding 15,633 candidate genes.
- We identified 269 genes significantly associated with dorsopathies (FDR_P < 0.05). Subsequent
- scrutiny uncovered four potential drug targets (NLRC4, CGREF1, KHK, RNF212) affecting
- dorsopathies through various intersecting methods. For clarity, Manhattan plots illustrated SMR
- results. Following gene identification, the HEIDI heterogeneity test (p_HEIDI > 0.05) sifted out
- 192 genes lacking horizontal pleiotropy. SMR locus plots further elucidated gene outcomes.
- 193 We proceeded with colocalization analyses to merge GWAS and blood eQTL data for genes passing
- the SMR test. This aimed to determine if these genes colocalized with the dorsopathies trait. The
- colocalization test results robustly supported colocalization between the trait and all four genes
- 196 (*NLRC4*: PP.H4 = 0.993, *CGREF1*: PP.H4 = 0.905, *KHK*: PP.H4 = 0.773, *RNF212*: PP.H4 = 0.923)
- meeting both SMR and HEIDI test criteria. Consequently, we identify these genes as top-priority
- 198 candidates for subsequent functional studies.

3.2 MR analyses Validates Potential Gene Causal Relationships

- Using cis-eQTL data from the eQTLGen Consortium, we conducted two-sample MR analyses on
- 202 European summary statistics of individuals with dorsopathies. The discovery cohort, consisting of
- 203 117,411 cases and 294,770 controls from the FinnGen cohort, underwent inverse variance weighted
- 204 (IVW) MR analyses to combine effect estimates from each genetic instrument. The analysis revealed
- associations between the genetically predicted expression of 956 genes and dorsopathies risk
- following multiple testing adjustments (FDR correction). Notably, NLRC4 (OR = 0.886, 95%CI =
- 0.855-0.917, FDR_P = 1.09e-11), CGREF1 (OR = 0.682, 95%CI = 0.585-0.794, FDR_P = 8.74e-07),
- KHK (OR = 0.936, 95% CI = 0.921-0.951, FDR P = 3.67e-16), and RNF212 (OR = 1.145, 95% CI =
- 209 1.056-1.241, FDR_P = 1.01e-03) were among the genes identified. To ensure the reliability of our
- 210 findings, we conducted tests for horizontal pleiotropy, which did not reveal any evidence of its
- 211 presence in the dataset. These additional analyses confirmed the absence of horizontal pleiotropy,
- bolstering the robustness and validity of our MR genetics findings.

3.3 Validation

213

214

215

3.3.1 TWAS & UTMOST Validates Transcriptome-level Causal Relationships

- 216 In our quest to enhance causal inference and gain deeper insights into genetic associations with
- dorsopathies, we conducted a TWAS analyses on the four genes identified in previous analyses,
- 218 utilizing Fusion and UTMOST software. This comprehensive approach aimed to elucidate the
- transcriptional associations of these genes with dorsopathies and bolster the evidence supporting their
- 220 potential causal role.
- The results revealed significant transcriptional associations for the four genes with dorsopathies, with
- all colocalization probabilities (PP.H4) exceeding 0.7. Specifically, elevated transcription levels of
- NLRC4 (Z score = -5.33068, P = 9.78E-08), CGREF1 (Z score = -4.7644, P = 1.89E-06), and KHK
- (Z score = -4.72939, P = 2.25E-06) were significantly correlated with a decreased risk of
- dorsopathies, whereas an increased transcription level of RNF212 (Z score = 3.751506, P =
- 226 0.000176) was significantly associated with an increased risk of dorsopathies. Notably, these TWAS
- findings were consistent with those from the SMR analyses, providing robust support for the
- transcriptional associations of these genes with dorsopathies.

229 3.3.2 MAGMA Validates Genome-level Causal Relationships

- We also conducted a GWAS analyses using MAGMA software on the quartet of genes highlighted in
- preceding studies. This approach aimed to illuminate the associations of these genes with
- dorsopathies at the genome level, thereby reinforcing the evidence underpinning their potential causal
- 233 involvement.
- Based on the MAGMA analyses, we identified 855 significant genes that passed the FDR test. The
- outcomes unveiled noteworthy genome-level associations for the aforementioned genes with
- dorsopathies. Specifically, heightened transcription levels of *NLRC4* (FDR_P = 0.01851868),
- 237 CGREF1 (P = 0.002068503), and KHK (P = 0.009814817) exhibited significant correlations with
- reduced risk of dorsopathies, whereas increased transcription levels of RNF212 (P = 0.00202954)
- were significantly linked with elevated risk of dorsopathies. Importantly, these GWAS findings
- corroborated those from the SMR analyses, thereby fortifying the robustness of the transcriptional
- associations of these genes with dorsopathies.

3.4 Methylation analysis & Mediation analysis

- We evaluated the influence of cg23387401 on RNF212 expression ($\beta = -0.52$, P = 2.08e-14) and its
- link to dorsopathies risk ($\beta = 0.19$, P = 1.20E-07). From these findings, we identified how gene-
- mediated methylation impacts dorsopathies risk ($\beta = -0.10$, P = 1.35E-05), with an observed overall
- 247 effect ($\beta = -0.10$, P = 2.68E-06) indicating a 93.79% intermediate effect proportion. This suggests
- 248 that the rise in cg23387401 is wholly mediated by RNF212, leading to reduced dorsopathies risk.
- Likewise, we assessed cg26638505's impact on *NLRC4* expression ($\beta = -0.81$, P = 1.25E-09) and its
- association with dorsopathies risk ($\beta = -0.13$, P = 7.87E-09). These calculations revealed the
- influence of gene-mediated methylation sites on dorsopathies risk ($\beta = 0.11$, P = 2.87E-05), with an
- overall effect ($\beta = 0.09$, P = 1.43E-03) and an intermediate effect proportion of approximately
- 253 120.00%. This suggests that cg26638505 elevation is entirely mediated by NLRC4, reducing
- dorsopathies risk.

243

- We also analyzed cg18948125's effect on NLRC4 expression ($\beta = -0.93$, P = 1.72E-08) and its
- association with dorsopathies risk ($\beta = -0.13$, P = 7.87E-09). From this, we derived the impact of
- gene-mediated methylation sites on dorsopathies risk ($\beta = 0.12$, P = 5.50E-05), with an overall
- effect ($\beta = 0.12$, P = 5.59E-04) and an intermediate effect proportion of 104.41%. This suggests that
- 259 cg18948125 elevation primarily contributes to increased dorsopathies risk, mediated by NLRC4.
- Similarly, cg22740783's influence on *CGREF1* expression ($\beta = 0.32$, P = 7.71E-07) and its
- association with dorsopathies risk ($\beta = -0.38$, P = 2.12E-05) was calculated. This allowed us to
- identify the impact of gene-mediated methylation sites on dorsopathies risk ($\beta = -0.12$, P = 1.27E-
- 263 03), with an overall effect ($\beta = -0.13$, P = 1.63E-04) and an intermediate effect proportion of
- 92.24%. Hence, we propose that the elevation in cg22740783 is fully mediated by CGREF1, leading
- to decreased dorsopathies risk.
- Lastly, we evaluated cg06112415's impact on CGREF1 expression ($\beta = -0.34$, P = 1.75E-06) and its
- association with dorsopathies risk ($\beta = -0.38$, P = 2.12E-05). Through these assessments, we
- identified the effect of gene-mediated methylation sites on dorsopathies risk ($\beta = 0.13$, P = 1.49E-
- 269 03), with an overall effect ($\beta = 0.12$, P = 5.59E-04) and an intermediate effect proportion of
- 270 110.63%. This suggests that *cg06112415* elevation primarily contributes to increased dorsopathies
- risk, mediated by *CGREF1*.

4 Discussion

272

- 274 This study aimed to offer new perspectives and methods for the treatment and prevention of
- dorsopathies. In our research, the identification of candidate genes and the establishment of causal
- inference were conducted via MR methods, while the mediation analysis was used to explore disease
- related gene-mediated methylation sites. As a result, our study revealed four genes as potential
- 278 therapeutic targets for dorsopathies, including *NLRC4*, *CGREF1*, *KHK* and *RNF212*. Among these
- 279 genes, elevated transcription levels of the NLRC4, CGREF1 and KHK were significantly associated
- with a decreased risk of dorsopathies, whereas a raised transcription level of RNF212 was
- significantly related a higher risk of dorsopathies.

- In order to find the novel drug targets for dorsopathies, we employed an integrative analysis that
- combined colocalization with MR to assess causal genes for dorsopathies. Later, we conducted tests
- for horizontal pleiotropy to ensure the reliability of our MR genetics findings. In addition, TWAS
- analyses on NLRC4, CGREF1, KHK and RNF212 was conducted through Fusion and UTMOST
- software, which further illuminated the transcriptional associations of these genes with dorsopathies
- and bolstered the evidence supporting their potential causal role. Moreover, we conducted a GWAS
- analyses whose results were consistent with those from the SMR analyses, which reinforcing the
- evidence underpinning the potential causal association between these four genes with dorsopathies.
- Finally, we evaluated the influence of methylation sites on those genes expression and their links to
- dorsopathies. The results exhibited that the rise in *cg23387401* was entirely mediated by *RNF212*, the
- 292 elevations of cg26638505 and cg18948125 were primarily mediated by NLRC4, and the up-
- regulation of *cg06112415* was fully mediated by *CGREF1*, leading to increased dorsopathies risk;
- 294 while the rise of cg22740783 was totally mediated by CGREF1, resulting in decreased dorsopathies
- 295 risk.
- NOD-like receptors (NLRs) family caspase activation and recruitment domain-containing protein 4
- 297 (NLRC4) gene encodes NLRC4, which is mainly expressed in macrophages, neutrophils, dendritic
- cells and glial cells[26]. As a member of the caspase recruitment domain-containing *NLR* family,
- 299 NLRC4 partners with NLR family of apoptosis inhibitory proteins (NAIP) to assemble
- inflammasome complexes, which termed NAIP/NLRC4 inflammasomes[27]. Inflammasomes
- function as intracellular multi-protein platforms that are activated by pathogen-associated molecular
- 302 patterns or damage-associated molecular patterns, triggering innate immune reactions and
- inflammatory caspase-activation to defense pathogens and danger signals and maintain the
- homeostasis[27–29]. The activation of caspases results in the proteolytic activation of the pro-
- inflammatory cytokines interleukin-1β (IL-1β) and/or interleukin-18 (IL-18)[27]. Meanwhile,
- activated caspase-1 also cleaves gasdermin D, whose N-terminal fragments become inserted into cell
- membranes, thereby facilitating the release of more IL-1β and IL-18[28,29]. In particular,
- inflammasomes were classified into canonical inflammasomes, which activating caspase-1, and non-
- canonical inflammasomes, which primarily activate caspase-4 and/or caspase-5 in human cells[29].
- 310 Specifically, the NAIP/NLRC4 inflammasome serves as a spart of the innate immune response and
- senses a range of intracellular bacteria and bacterial components in the host cell cytosol, such as S.
- 312 typhimurium, Legionella pneumophila, flagellin and components of the virulence-associated type III
- secretion apparatus, thereby to mediate host defense against bacterial pathogens [26,27,30]. NAIP
- proteins function as specific cytosolic receptors for a variety of bacterial protein ligands[31], while
- 315 NLRC4 interacts directly with caspase-1 to induce cell death, such as the pyroptosis of macrophage,
- and to cause rapidly initiate inflammation and vascular fluid loss[26]. The localized effects of
- 317 NAIP/NLRC4 inflammasome could defend against bacterial pathogens. However, the aberrant
- activity of this cluster also leads to multiple clinical manifestations, including macrophage activation
- 319 syndrome, neonatal enterocolitis and autoimmune disorders[28,31], and promotes the process of
- some diseases, such as gliomas[29], premature rupture of membranes[26], ulcerative colitis[28],
- rheumatoid arthritis[30] and so on. Sim et al. found that non-canonical pathway molecules of
- 322 NAIP/NLRC4 inflammasomes, including caspase-4, caspase-5, and N-cleaved GSDMD, were
- significantly increased with each glioma grade [29]. Additionally, Zhu et al. reported that NLRC4 was
- 324 upregulated in the membranes of patients with premature rupture of fetal membranes and recruited
- more caspase-1, which promotes the process of rupture of fetal membranes by inducing apoptosis
- and degrading extracellular matrix[26]. The study of An et al. presented that the persistent activation
- of NAIP/NLRC4 inflammasome induces macrophage pyroptosis mediated by caspase1-dependent
- 328 cleavage of GSDMD and releases proinflammatory cytokines including IL-1b and IL-18, facilitating

- 329 the occurrence and progression of UC[28]. In addition, research conducted by Delgado-Arévalo et al.
- indicated that NLRC4 as an inflammasome sensor differentially upregulated in CD1c+ cDC from
- patients with rheumatoid arthritis, and this sensor seems to be nonredundantly involved in the
- detection of intracellular dsDNA[30]. Nevertheless, our research observed the significantly inhibitory
- effect of up-regulated *NLRC4* expression on dorsopathies. Thus, further research on the roles and
- mechanisms of *NLRC4* and inflammatsome in the progress of dorsopathies is needed.
- 335 Cell growth regulator with EF-hand domain 1 (CGREF1) gene encodes a novel secretory protein
- with 2 Ca2+-binding EF-hand domains which plays an important role in eukaryotic cellular
- signaling[32]. CGREF1 mRNA has high expressions in HCT116, H1299 and HepG2 cells while
- expressing at low levels in other cell lines including Raji, Jurkat, BT325, PC12[32]. Mechanistically,
- 339 *CGREF1* is regulated by p53[33], and the overexpression of *CGREF1* significantly inhibits the
- transcriptional activity of AP-1, reduces the phosphorylation of ERK (extracellular signal-regulated
- kinases) and p38 MAPK (mitogen-activated protein kinases), and suppresses the proliferation of
- 342 HEK293T and HCT116 cells[32]. Furthermore, CGREF1 can decrease the percent of G2/M and S
- phase and repress cell proliferation while overexpressing[32]. We found that the increased expression
- of CGREF1 is significantly related to the decreased risk of dorsopathies. In the research of Xiang et
- al., the colorectal cancer patients with higher expression of *CGREF1* were found to have significantly
- better overall survival than patients with lower expression, and the role of *CGREF1* in the prognosis
- of Early-onset colorectal cancer was reported[33]. Furthermore, Xie et al. observed that CGREF1
- expression were high in the tissue of osteosarcoma patients while it were lowly expressed in normal
- 349 tissue, and speculated that CGREF1 can predict drug resistance to osteosarcoma[34]. However, the
- biological function of CGREF1 is poorly explored, and further study for its mechanisms and roles in
- 351 these diseases is warranted.
- 352 Ketohexokinase (*KHK*) is an enzyme that phosphorylates fructose to produce fructose-1-phosphate
- 353 (F-1-P) at the first rate-limiting step in fructose metabolism[35,36]. The gene KHK encodes two
- isoforms, KHK-C and KHK-A. Considered as the primary enzyme in fructose metabolism, KHK-C is
- exclusively expressed in a few tissues, especially in the liver, and drives the aforementioned reaction
- 356 rapidly, resulting in the accumulation of uric acid and transient depletion of intracellular phosphate
- and ATP[35–38]. In the contrary, KHK-A has a much weaker affinity and a higher Michaelis
- constant for fructose[38]. However, KHK-A can directly phosphorylate phosphoribosyl
- 359 pyrophosphate synthetase 1 (PRPS1) by prevention of inhibitory nucleotide binding and facilitation
- of ATP binding[37]. As a result, KHK-A improves nucleic acid synthesis and promotes the G1/S
- 361 phase transition in the cell cycle, accelerating cell proliferation [36,38].
- Recent studies have highlighted the importance of KHK as the key mechanism stimulating the
- various adverse metabolic effects of fructose, such as impaired insulin sensitivity,
- 364 hypertriglyceridemia, and oxidative stress[35]. In addition, fructose metabolism seems to provide
- cancer cells with the supplementary fuel required for proliferation and metastasis in colon cancer, and
- 366 glioma[36,38]. Moreover, alternated expression of KHK is also related to several diseases. For
- instance, knocked down the expression of *KHK* dramatically reduced fructose-induced production of
- reactive oxidative species (ROS) in proximal tubular cells[35], indicating the association between
- 369 KHK and ROS. Furthermore, KHK-A activates and upregulates PRPS1, which could lead to
- enhanced nucleic acid synthesis for tumourigenesis[38]. Kim et al. reported that most cancer cell
- 371 lines predominantly expressed KHK-A rather than KHK-C, and KHK-A overexpression could
- augment cell invasion[36]. Moreover, in their study, upon fructose stimulation, KHK-A acted as a
- 373 nuclear protein kinase and triggered Epithelial-mesenchymal transition in breast cancer, promoting
- breast cancer metastasis[36]. Besides, loss-of-function variants in KHK can cause essential

- fructosuria, an autosomal recessive disease characterized by intermittent appearance of fructose in the
- urine[39]. Yang et al. found the the overexpression of KHK-A in cell lines of oesophageal squamous
- cell carcinoma, which may finally promote the proliferation, tumourigenicity and motility of ESCC
- cells[38]. Similarly, KHK-A was considered to play an instrumental role in promoting de novo
- nucleic acid synthesis and hepatocellular carcinoma development[37]. In our study, the raised
- expression of KHK is found to be positively related to decreased risk of dorsopathies. In oder to
- understand the mechanism of changed expression level of KHK in dorsopathies, further research are
- 382 needed.
- Regulatory factor X2 (RFX2) gene is essential for maintaining normal spermatogenesis and involved
- in spermatogenesis impairment and male infertility in mice[40]. In particular, Ring finger protein 212
- 385 (RNF212) gene is important for crossing over and chiasma formation during meiosis[41]. Mouse
- 386 Rnf212 has a central role in designating crossover sites and coupling chromosome synapsis to the
- formation of crossover-specific recombination complexes. In humans, RNF212 has been associated
- with variation in the genome-wide recombination rate[41]. The protein encoded by RNF212 has
- homology to two meiotic procrossover factors: Zip3 and ZHP-3[42]. It functions to couple
- 390 chromosome synapsis to the formation of crossover-specific recombination complexes [43].
- 391 Moreover, with the symbolic RING-finger domains, *RNF212* protein is a RING-family E3-ligase for
- 392 Small ubiquitin-like protein (SUMO), and the latter plays an important role in assembly and
- disassembly of synaptonemal complex by regulating protein–protein inter action during
- meiosis[42,43,43]. In addition, RNF212 stabilizes association of a subset of MutSγ complexes with
- recombination sites[42,44]. MutSy complex is a kind of meiosis-specific recombination factors,
- working as an attractive target for non-crossover/crossover differentiation[42]. It binds and stabilizes
- 397 DNA strand-exchange intermediates to promote both homolog synapsis and crossingover[44]. In
- mammals, every pair of chromosomes obtains at least one crossover, while the majority of
- 399 recombination sites yield non-crossovers. Non-crossovers are inferred to arise from the disassembly
- of D-loops and annealing of DNA double-strand breaks ends in a process termed synthesis dependent
- strand annealing[42]. Designation of crossovers involves the formation of metastable joint molecules
- and selective localization of SUMO-ligase RNF212 to a minority of recombination sites where it
- 403 stabilizes pertinent factors, such as MutSγ[42,44]. Furthermore, this differential RNF212-dependent
- stabilization of key recombination proteins at precrossover sites is thought to be the basic feature of
- 405 crossover/non-crossover differentiation[42]. It is suggested that RNF212-mediated SUMOylation
- may stabilizes the association of MutSy with nascent crossover CO intermediates in a number of
- ways, such as promoting protein-protein interactions, altering ATP binding and hydrolysis (which
- 408 modulate the binding and dissociation of MutSy complexes) or antagonizing ubiquitin-dependent
- 409 protein turnover[41,42].
- 410 Insufficient RNF212 accumulating at recombination sites can lead to crossing-over stochastically
- fails[43]. Fujiwara et al. reported that *Rnf212* knock out (KO) in mice leads to infertility of male and
- female due to the loss of SPCs(spermatocytes) at post-anaphase stage. Moreover, crossing over is
- diminished by $\geq 90\%$ in Rnf212——mice[43]. In particular, the Rnf212 KO spermatocytes lack
- chiasmata and exhibit depletion of spermatids and mature spermatozoa[41]. A nonsense mutation in
- 415 the *Rnf212* gene was discovered in repro57 mutant mice, and this mutant mice exhibited male
- 416 infertility, arrest of spermatogenesis in meiosis, and defects in cytological markers of recombination
- and chiasma formation, which is similar to the *Rnf212* KO phenotype[41]. In humans, the rate of
- 418 crossing-over varies significantly between individuals, and higher maternal crossover rates have been
- associated with greater fecundity[42]. However, in the absence of RNF212, designation of crossover
- sites fails because no MutSy complexes are stabilized beyond early pachynema[44]. Yu et al.
- detected that the frequencies of allele C and the genotype CC at the rs4045481 locus in RNF212 gene

- were significantly higher in patients with azoospermia in comparison with controls. Furthermore,
- 423 they reported that homozygous of allele C (genotype CC) may decrease the activity of pre-mRNA
- due to the disappearance of the binding motifs of SRSF5, leading to the reduced expression of
- 425 RNF212 and influencing normal spermatogenesis, consequently increasing ther risk of
- azoospermia[40]. Nevertheless, we found that the increased expression of RNF212 exhibited a
- positive correlation with dorsopathies. The influence of raised expression of *RNF212* is poor
- 428 classified, and further researches are required to illustrate the mechanism of increased RNF212 level
- and dorsopathies.

438

441

445

448

449

- To summary, our study revealed the causal associations between the genetically predicted expression
- of four genes (NLRC4, CGREF1, KHK and RNF212) and dorsopathies risk, which offers new
- perspectives and strategies for the improved diagnosis, treatment and prevention of dorsopathies.
- Based on our results, we hypothesized that increased expression level of *NLRC4*, *CGREF1* and *KHK*
- are associated with decreased risk of dorsopathies, while the increased expression level of *RNF212*
- has the opposite effect. Moreover, further study focusing on the mechanism of these expression
- changes in dorsopathies are needed, and future clinical studies should be conducted.

5 Acknowledgements

- The authors appreciate the publicly available data of the FinnGen consortium, the eQTLGen
- consortium, the GTEx project, and the MRC IEU OpenGWAS database.

442 **6** Conflict of interest

- The authors declare that the research was conducted in the absence of any commercial or financial
- relationships that could be construed as a potential conflict of interest.

446 7 Funding

The study and publishing of this article were not supported by any funding.

8 Reference

- 450 [1] L.B. Connelly, A. Woolf, P. Brooks, Cost-Effectiveness of Interventions for Musculoskeletal
- Conditions, in: D.T. Jamison, J.G. Breman, A.R. Measham, G. Alleyne, M. Claeson, D.B.
- 452 Evans, P. Jha, A. Mills, P. Musgrove (Eds.), Disease Control Priorities in Developing Countries,
- 2nd ed., The International Bank for Reconstruction and Development / The World Bank,
- Washington (DC), 2006. http://www.ncbi.nlm.nih.gov/books/NBK11713/ (accessed April 30,
- 455 2024).

- L. March, E.U.R. Smith, D.G. Hoy, M.J. Cross, L. Sanchez-Riera, F. Blyth, R. Buchbinder, T.
- Vos, A.D. Woolf, Burden of disability due to musculoskeletal (MSK) disorders, Best Pract Res
- 458 Clin Rheumatol 28 (2014) 353–366. https://doi.org/10.1016/j.berh.2014.08.002.
- 459 [3] R. Shiri, J. Karppinen, P. Leino-Arjas, S. Solovieva, E. Viikari-Juntura, The association
- between smoking and low back pain: a meta-analysis, Am J Med 123 (2010) 87.e7–35.
- 461 https://doi.org/10.1016/j.amjmed.2009.05.028.
- 462 [4] R. Shiri, J. Karppinen, P. Leino-Arjas, S. Solovieva, E. Viikari-Juntura, The association
- between obesity and low back pain: a meta-analysis, Am J Epidemiol 171 (2010) 135–154.
- 464 https://doi.org/10.1093/aje/kwp356.
- 465 [5] A. Koyanagi, A. Stickley, N. Garin, M. Miret, J.L. Ayuso-Mateos, M. Leonardi, S. Koskinen,
- A. Galas, J.M. Haro, The association between obesity and back pain in nine countries: a cross-
- sectional study, BMC Public Health 15 (2015) 123. https://doi.org/10.1186/s12889-015-1362-9.
- 468 [6] M. Smuck, M.-C.J. Kao, N. Brar, A. Martinez-Ith, J. Choi, C.C. Tomkins-Lane, Does physical
- activity influence the relationship between low back pain and obesity?, Spine J 14 (2014) 209–
- 470 216. https://doi.org/10.1016/j.spinee.2013.11.010.
- 471 [7] T.W. Strine, J.M. Hootman, US national prevalence and correlates of low back and neck pain
- among adults, Arthritis Rheum 57 (2007) 656–665. https://doi.org/10.1002/art.22684.
- 473 [8] M. Scherer, H. Hansen, J. Gensichen, K. Mergenthal, S. Riedel-Heller, S. Weyerer, W. Maier,
- A. Fuchs, H. Bickel, G. Schön, B. Wiese, H.-H. König, H. van den Bussche, I. Schäfer,
- Association between multimorbidity patterns and chronic pain in elderly primary care patients:
- a cross-sectional observational study, BMC Fam Pract 17 (2016) 68.
- 477 https://doi.org/10.1186/s12875-016-0468-1.
- 478 [9] G. Davey Smith, G. Hemani, Mendelian randomization: genetic anchors for causal inference in
- 479 epidemiological studies, Human Molecular Genetics 23 (2014) R89-98.
- 480 https://doi.org/10.1093/hmg/ddu328.
- 481 [10] M.K. Georgakis, D. Gill, Mendelian Randomization Studies in Stroke: Exploration of Risk
- Factors and Drug Targets With Human Genetic Data, Stroke 52 (2021) 2992–3003.
- 483 https://doi.org/10.1161/STROKEAHA.120.032617.
- 484 [11] M.V. Holmes, M. Ala-Korpela, G.D. Smith, Mendelian randomization in cardiometabolic
- disease: challenges in evaluating causality, Nature Reviews. Cardiology 14 (2017) 577–590.
- 486 https://doi.org/10.1038/nrcardio.2017.78.
- 487 [12] Y. Chen, X. Xu, L. Wang, K. Li, Y. Sun, L. Xiao, J. Dai, M. Huang, Y. Wang, D.W. Wang,
- Genetic insights into the apeutic targets for a artic aneurysms: A Mendelian randomization
- 489 study, eBioMedicine 83 (2022) 104199. https://doi.org/10.1016/j.ebiom.2022.104199.
- 490 [13] J. Lin, J. Zhou, Y. Xu, Potential drug targets for multiple sclerosis identified through Mendelian
- randomization analysis, Brain 146 (2023) 3364–3372. https://doi.org/10.1093/brain/awad070.

- [14] Y. Wang, F. Liu, L. Sun, Y. Jia, P. Yang, D. Guo, M. Shi, A. Wang, G.-C. Chen, Y. Zhang, Z.
 Zhu, Association between human blood metabolome and the risk of breast cancer, Breast
 Cancer Res 25 (2023) 9. https://doi.org/10.1186/s13058-023-01609-4.
- 495 [15] S. Shah, A. Henry, C. Roselli, H. Lin, G. Sveinbjörnsson, G. Fatemifar, Å.K. Hedman, J.B. 496 Wilk, M.P. Morley, M.D. Chaffin, A. Helgadottir, N. Verweij, A. Dehghan, P. Almgren, C. 497 Andersson, K.G. Aragam, J. Ärnlöv, J.D. Backman, M.L. Biggs, H.L. Bloom, J. Brandimarto, 498 M.R. Brown, L. Buckbinder, D.J. Carey, D.I. Chasman, X. Chen, X. Chen, J. Chung, W. 499 Chutkow, J.P. Cook, G.E. Delgado, S. Denaxas, A.S. Doney, M. Dörr, S.C. Dudley, M.E. Dunn, 500 G. Engström, T. Esko, S.B. Felix, C. Finan, I. Ford, M. Ghanbari, S. Ghasemi, V. Giedraitis, F. 501 Giulianini, J.S. Gottdiener, S. Gross, D.F. Guðbjartsson, R. Gutmann, C.M. Haggerty, P. van 502 der Harst, C.L. Hyde, E. Ingelsson, J.W. Jukema, M. Kavousi, K.-T. Khaw, M.E. Kleber, L. 503 Køber, A. Koekemoer, C. Langenberg, L. Lind, C.M. Lindgren, B. London, L.A. Lotta, R.C. 504 Lovering, J. Luan, P. Magnusson, A. Mahajan, K.B. Margulies, W. März, O. Melander, I.R. 505 Mordi, T. Morgan, A.D. Morris, A.P. Morris, A.C. Morrison, M.W. Nagle, C.P. Nelson, A. 506 Niessner, T. Niiranen, M.L. O'Donoghue, A.T. Owens, C.N.A. Palmer, H.M. Parry, M. Perola, 507 E. Portilla-Fernandez, B.M. Psaty, Regeneron Genetics Center, K.M. Rice, P.M. Ridker, S.P.R. 508 Romaine, J.I. Rotter, P. Salo, V. Salomaa, J. van Setten, A.A. Shalaby, D.T. Smelser, N.L. 509 Smith, S. Stender, D.J. Stott, P. Svensson, M.-L. Tammesoo, K.D. Taylor, M. Teder-Laving, A. 510 Teumer, G. Thorgeirsson, U. Thorsteinsdottir, C. Torp-Pedersen, S. Trompet, B. Tyl, A.G. 511 Uitterlinden, A. Veluchamy, U. Völker, A.A. Voors, X. Wang, N.J. Wareham, D. Waterworth, P.E. Weeke, R. Weiss, K.L. Wiggins, H. Xing, L.M. Yerges-Armstrong, B. Yu, F. Zannad, J.H. 512 513 Zhao, H. Hemingway, N.J. Samani, J.J.V. McMurray, J. Yang, P.M. Visscher, C. Newton-Cheh, 514 A. Malarstig, H. Holm, S.A. Lubitz, N. Sattar, M.V. Holmes, T.P. Cappola, F.W. Asselbergs, 515 A.D. Hingorani, K. Kuchenbaecker, P.T. Ellinor, C.C. Lang, K. Stefansson, J.G. Smith, R.S. 516 Vasan, D.I. Swerdlow, R.T. Lumbers, Genome-wide association and Mendelian randomisation 517 analysis provide insights into the pathogenesis of heart failure, Nature Communications 11
- 518 (2020) 163. https://doi.org/10.1038/s41467-019-13690-5. 519 [16] M.I. Kurki, J. Karjalainen, P. Palta, T.P. Sipilä, K. Kristiansson, K.M. Donner, M.P. Reeve, H. 520 Laivuori, M. Aavikko, M.A. Kaunisto, A. Loukola, E. Lahtela, H. Mattsson, P. Laiho, P. Della 521 Briotta Parolo, A.A. Lehisto, M. Kanai, N. Mars, J. Rämö, T. Kiiskinen, H.O. Heyne, K. 522 Veerapen, S. Rüeger, S. Lemmelä, W. Zhou, S. Ruotsalainen, K. Pärn, T. Hiekkalinna, S. 523 Koskelainen, T. Paajanen, V. Llorens, J. Gracia-Tabuenca, H. Siirtola, K. Reis, A.G. Elnahas, 524 B. Sun, C.N. Foley, K. Aalto-Setälä, K. Alasoo, M. Arvas, K. Auro, S. Biswas, A. Bizaki-525 Vallaskangas, O. Carpen, C.-Y. Chen, O.A. Dada, Z. Ding, M.G. Ehm, K. Eklund, M. Färkkilä, 526 H. Finucane, A. Ganna, A. Ghazal, R.R. Graham, E.M. Green, A. Hakanen, M. Hautalahti, A.K. 527 Hedman, M. Hiltunen, R. Hinttala, I. Hovatta, X. Hu, A. Huertas-Vazquez, L. Huilaja, J. 528 Hunkapiller, H. Jacob, J.-N. Jensen, H. Joensuu, S. John, V. Julkunen, M. Jung, J. Junttila, K. 529 Kaarniranta, M. Kähönen, R. Kajanne, L. Kallio, R. Kälviäinen, J. Kaprio, FinnGen, N. 530 Kerimov, J. Kettunen, E. Kilpeläinen, T. Kilpi, K. Klinger, V.-M. Kosma, T. Kuopio, V. Kurra, 531 T. Laisk, J. Laukkanen, N. Lawless, A. Liu, S. Longerich, R. Mägi, J. Mäkelä, A. Mäkitie, A. 532 Malarstig, A. Mannermaa, J. Maranville, A. Matakidou, T. Meretoja, S.V. Mozaffari, M.E.K. 533 Niemi, M. Niemi, T. Niiranen, C.J. O Donnell, M.E. Obeidat, G. Okafo, H.M. Ollila, A. 534 Palomäki, T. Palotie, J. Partanen, D.S. Paul, M. Pelkonen, R.K. Pendergrass, S. Petrovski, A. 535 Pitkäranta, A. Platt, D. Pulford, E. Punkka, P. Pussinen, N. Raghavan, F. Rahimov, D. Rajpal, 536 N.A. Renaud, B. Riley-Gillis, R. Rodosthenous, E. Saarentaus, A. Salminen, E. Salminen, V. 537 Salomaa, J. Schleutker, R. Serpi, H.-Y. Shen, R. Siegel, K. Silander, S. Siltanen, S. Soini, H.

Soininen, J.H. Sul, I. Tachmazidou, K. Tasanen, P. Tienari, S. Toppila-Salmi, T. Tukiainen, T.

- Tuomi, J.A. Turunen, J.C. Ulirsch, F. Vaura, P. Virolainen, J. Waring, D. Waterworth, R. Yang,
- M. Nelis, A. Reigo, A. Metspalu, L. Milani, T. Esko, C. Fox, A.S. Havulinna, M. Perola, S.
- Ripatti, A. Jalanko, T. Laitinen, T.P. Mäkelä, R. Plenge, M. McCarthy, H. Runz, M.J. Daly, A.
- Palotie, FinnGen provides genetic insights from a well-phenotyped isolated population, Nature
- 543 613 (2023) 508–518. https://doi.org/10.1038/s41586-022-05473-8.
- 544 [17] U. Võsa, A. Claringbould, H.-J. Westra, M.J. Bonder, P. Deelen, B. Zeng, H. Kirsten, A. Saha,
- R. Kreuzhuber, S. Yazar, H. Brugge, R. Oelen, D.H. de Vries, M.G.P. van der Wijst, S. Kasela,
- N. Pervjakova, I. Alves, M.-J. Favé, M. Agbessi, M.W. Christiansen, R. Jansen, I. Seppälä, L.
- Tong, A. Teumer, K. Schramm, G. Hemani, J. Verlouw, H. Yaghootkar, R. Sönmez Flitman, A.
- Brown, V. Kukushkina, A. Kalnapenkis, S. Rüeger, E. Porcu, J. Kronberg, J. Kettunen, B. Lee,
- F. Zhang, T. Qi, J.A. Hernandez, W. Arindrarto, F. Beutner, BIOS Consortium, i2QTL
- Consortium, J. Dmitrieva, M. Elansary, B.P. Fairfax, M. Georges, B.T. Heijmans, A.W. Hewitt,
- M. Kähönen, Y. Kim, J.C. Knight, P. Kovacs, K. Krohn, S. Li, M. Loeffler, U.M. Marigorta, H.
- Mei, Y. Momozawa, M. Müller-Nurasyid, M. Nauck, M.G. Nivard, B.W.J.H. Penninx, J.K.
- Pritchard, O.T. Raitakari, O. Rotzschke, E.P. Slagboom, C.D.A. Stehouwer, M. Stumvoll, P.
- Sullivan, P.A.C. 't Hoen, J. Thiery, A. Tönjes, J. van Dongen, M. van Iterson, J.H. Veldink, U.
- Völker, R. Warmerdam, C. Wijmenga, M. Swertz, A. Andiappan, G.W. Montgomery, S.
- Ripatti, M. Perola, Z. Kutalik, E. Dermitzakis, S. Bergmann, T. Frayling, J. van Meurs, H.
- Prokisch, H. Ahsan, B.L. Pierce, T. Lehtimäki, D.I. Boomsma, B.M. Psaty, S.A. Gharib, P.
- Awadalla, L. Milani, W.H. Ouwehand, K. Downes, O. Stegle, A. Battle, P.M. Visscher, J.
- Yang, M. Scholz, J. Powell, G. Gibson, T. Esko, L. Franke, Large-scale cis- and trans-eQTL
- analyses identify thousands of genetic loci and polygenic scores that regulate blood gene
- expression, Nature Genetics 53 (2021) 1300–1310. https://doi.org/10.1038/s41588-021-00913-
- 562 z.
- 563 [18] GTEx Consortium, The GTEx Consortium atlas of genetic regulatory effects across human
- tissues, Science (New York, N.Y.) 369 (2020) 1318–1330.
- 565 https://doi.org/10.1126/science.aaz1776.
- 566 [19] Z. Z, Z, F, H. H, B. A, R. Mr, P. Je, M. Gw, G. Me, W. Nr, V. Pm, Y. J, Integration of summary
- data from GWAS and eQTL studies predicts complex trait gene targets, Nature Genetics 48
- 568 (2016). https://doi.org/10.1038/ng.3538.
- 569 [20] C.A. de Leeuw, J.M. Mooij, T. Heskes, D. Posthuma, MAGMA: generalized gene-set analysis
- of GWAS data, PLoS Comput Biol 11 (2015) e1004219.
- 571 https://doi.org/10.1371/journal.pcbi.1004219.
- 572 [21] The 1000 Genomes Project Consortium, Corresponding authors, A. Auton, G.R. Abecasis,
- 573 Steering committee, D.M. Altshuler, R.M. Durbin, G.R. Abecasis, D.R. Bentley, A.
- 574 Chakravarti, A.G. Clark, P. Donnelly, E.E. Eichler, P. Flicek, S.B. Gabriel, R.A. Gibbs, E.D.
- Green, M.E. Hurles, B.M. Knoppers, J.O. Korbel, E.S. Lander, C. Lee, H. Lehrach, E.R.
- 576 Mardis, G.T. Marth, G.A. McVean, D.A. Nickerson, J.P. Schmidt, S.T. Sherry, J. Wang, R.K.
- Wilson, Production group, Baylor College of Medicine, R.A. Gibbs, E. Boerwinkle, H.
- Doddapaneni, Y. Han, V. Korchina, C. Kovar, S. Lee, D. Muzny, J.G. Reid, Y. Zhu, BGI-
- Shenzhen, J. Wang, Y. Chang, Q. Feng, X. Fang, X. Guo, M. Jian, H. Jiang, X. Jin, T. Lan, G.
- Li, J. Li, Y. Li, S. Liu, X. Liu, Y. Lu, X. Ma, M. Tang, B. Wang, G. Wang, H. Wu, R. Wu, X.
- Xu, Y. Yin, D. Zhang, W. Zhang, J. Zhao, M. Zhao, X. Zheng, Broad Institute of MIT and
- Harvard, E.S. Lander, D.M. Altshuler, S.B. Gabriel, N. Gupta, Coriell Institute for Medical

583 Research, N. Gharani, L.H. Toji, N.P. Gerry, A.M. Resch, European Molecular Biology 584 Laboratory, European Bioinformatics Institute, P. Flicek, J. Barker, L. Clarke, L. Gil, S.E. Hunt, 585 G. Kelman, E. Kulesha, R. Leinonen, W.M. McLaren, R. Radhakrishnan, A. Roa, D. Smirnov, 586 R.E. Smith, I. Streeter, A. Thormann, I. Toneva, B. Vaughan, X. Zheng-Bradley, Illumina, D.R. 587 Bentley, R. Grocock, S. Humphray, T. James, Z. Kingsbury, Max Planck Institute for Molecular 588 Genetics, H. Lehrach, R. Sudbrak, M.W. Albrecht, V.S. Amstislavskiy, T.A. Borodina, M. 589 Lienhard, F. Mertes, M. Sultan, B. Timmermann, M.-L. Yaspo, McDonnell Genome Institute at 590 Washington University, E.R. Mardis, R.K. Wilson, L. Fulton, R. Fulton, US National Institutes 591 of Health, S.T. Sherry, V. Ananiev, Z. Belaia, D. Beloslyudtsev, N. Bouk, C. Chen, D. Church, 592 R. Cohen, C. Cook, J. Garner, T. Hefferon, M. Kimelman, C. Liu, J. Lopez, P. Meric, C. 593 O'Sullivan, Y. Ostapchuk, L. Phan, S. Ponomarov, V. Schneider, E. Shekhtman, K. Sirotkin, D. 594 Slotta, H. Zhang, University of Oxford, G.A. McVean, Wellcome Trust Sanger Institute, R.M. 595 Durbin, S. Balasubramaniam, J. Burton, P. Danecek, T.M. Keane, A. Kolb-Kokocinski, S. 596 McCarthy, J. Stalker, M. Quail, Analysis group, Affymetrix, J.P. Schmidt, C.J. Davies, J. 597 Gollub, T. Webster, B. Wong, Y. Zhan, Albert Einstein College of Medicine, A. Auton, C.L. 598 Campbell, Y. Kong, A. Marcketta, Baylor College of Medicine, R.A. Gibbs, F. Yu, L. Antunes, 599 M. Bainbridge, D. Muzny, A. Sabo, Z. Huang, BGI-Shenzhen, J. Wang, L.J.M. Coin, L. Fang, 600 X. Guo, X. Jin, G. Li, Q. Li, Y. Li, Z. Li, H. Lin, B. Liu, R. Luo, H. Shao, Y. Xie, C. Ye, C. Yu, F. Zhang, H. Zheng, H. Zhu, Bilkent University, C. Alkan, E. Dal, F. Kahveci, Boston College, 601 602 G.T. Marth, E.P. Garrison, D. Kural, W.-P. Lee, W. Fung Leong, M. Stromberg, A.N. Ward, J. 603 Wu, M. Zhang, Broad Institute of MIT and Harvard, M.J. Daly, M.A. DePristo, R.E. Handsaker, 604 D.M. Altshuler, E. Banks, G. Bhatia, G. Del Angel, S.B. Gabriel, G. Genovese, N. Gupta, H. Li, 605 S. Kashin, E.S. Lander, S.A. McCarroll, J.C. Nemesh, R.E. Poplin, Cold Spring Harbor 606 Laboratory, S.C. Yoon, J. Lihm, V. Makarov, Cornell University, A.G. Clark, S. Gottipati, A. 607 Keinan, J.L. Rodriguez-Flores, European Molecular Biology Laboratory, J.O. Korbel, T. 608 Rausch, M.H. Fritz, A.M. Stütz, European Molecular Biology Laboratory, European 609 Bioinformatics Institute, P. Flicek, K. Beal, L. Clarke, A. Datta, J. Herrero, W.M. McLaren, 610 G.R.S. Ritchie, R.E. Smith, D. Zerbino, X. Zheng-Bradley, Harvard University, P.C. Sabeti, I. 611 Shlyakhter, S.F. Schaffner, J. Vitti, Human Gene Mutation Database, D.N. Cooper, E.V. Ball, 612 P.D. Stenson, Illumina, D.R. Bentley, B. Barnes, M. Bauer, R. Keira Cheetham, A. Cox, M. 613 Eberle, S. Humphray, S. Kahn, L. Murray, J. Peden, R. Shaw, Icahn School of Medicine at 614 Mount Sinai, E.E. Kenny, Louisiana State University, M.A. Batzer, M.K. Konkel, J.A. Walker, 615 Massachusetts General Hospital, D.G. MacArthur, M. Lek, Max Planck Institute for Molecular 616 Genetics, R. Sudbrak, V.S. Amstislavskiy, R. Herwig, McDonnell Genome Institute at 617 Washington University, E.R. Mardis, L. Ding, D.C. Koboldt, D. Larson, K. Ye, McGill 618 University, S. Gravel, National Eye Institute, NIH, A. Swaroop, E. Chew, New York Genome 619 Center, T. Lappalainen, Y. Erlich, M. Gymrek, T. Frederick Willems, Ontario Institute for 620 Cancer Research, J.T. Simpson, Pennsylvania State University, M.D. Shriver, Rutgers Cancer 621 Institute of New Jersey, J.A. Rosenfeld, Stanford University, C.D. Bustamante, S.B. Montgomery, F.M. De La Vega, J.K. Byrnes, A.W. Carroll, M.K. DeGorter, P. Lacroute, B.K. 622 623 Maples, A.R. Martin, A. Moreno-Estrada, S.S. Shringarpure, F. Zakharia, Tel-Aviv University, 624 E. Halperin, Y. Baran, The Jackson Laboratory for Genomic Medicine, C. Lee, E. Cerveira, J. 625 Hwang, A. Malhotra, D. Plewczynski, K. Radew, M. Romanovitch, C. Zhang, Thermo Fisher Scientific, F.C.L. Hyland, Translational Genomics Research Institute, D.W. Craig, A. 626 627 Christoforides, N. Homer, T. Izatt, A.A. Kurdoglu, S.A. Sinari, K. Squire, US National 628 Institutes of Health, S.T. Sherry, C. Xiao, University of California, San Diego, J. Sebat, D. 629 Antaki, M. Gujral, A. Noor, K. Ye, University of California, San Francisco, E.G. Burchard, 630 R.D. Hernandez, C.R. Gignoux, University of California, Santa Cruz, D. Haussler, S.J. 631 Katzman, W. James Kent, University of Chicago, B. Howie, University College London, A.

632 Ruiz-Linares, University of Geneva, E.T. Dermitzakis, University of Maryland School of 633 Medicine, S.E. Devine, University of Michigan, G.R. Abecasis, H. Min Kang, J.M. Kidd, T. 634 Blackwell, S. Caron, W. Chen, S. Emery, L. Fritsche, C. Fuchsberger, G. Jun, B. Li, R. Lyons, C. Scheller, C. Sidore, S. Song, E. Sliwerska, D. Taliun, A. Tan, R. Welch, M. Kate Wing, X. 635 636 Zhan, University of Montréal, P. Awadalla, A. Hodgkinson, University of North Carolina at 637 Chapel Hill, Y. Li, University of North Carolina at Charlotte, X. Shi, A. Quitadamo, University 638 of Oxford, G. Lunter, G.A. McVean, J.L. Marchini, S. Myers, C. Churchhouse, O. Delaneau, A. 639 Gupta-Hinch, W. Kretzschmar, Z. Iqbal, I. Mathieson, A. Menelaou, A. Rimmer, D.K. Xifara, 640 University of Puerto Rico, T.K. Oleksyk, University of Texas Health Sciences Center at 641 Houston, Y. Fu, X. Liu, M. Xiong, University of Utah, L. Jorde, D. Witherspoon, J. Xing, 642 University of Washington, E.E. Eichler, B.L. Browning, S.R. Browning, F. Hormozdiari, P.H. 643 Sudmant, Weill Cornell Medical College, E. Khurana, Wellcome Trust Sanger Institute, R.M. 644 Durbin, M.E. Hurles, C. Tyler-Smith, C.A. Albers, Q. Ayub, S. Balasubramaniam, Y. Chen, V. 645 Colonna, P. Danecek, L. Jostins, T.M. Keane, S. McCarthy, K. Walter, Y. Xue, Yale University, 646 M.B. Gerstein, A. Abyzov, S. Balasubramanian, J. Chen, D. Clarke, Y. Fu, A.O. Harmanci, M. 647 Jin, D. Lee, J. Liu, X. Jasmine Mu, J. Zhang, Y. Zhang, Structural variation group, BGI-648 Shenzhen, Y. Li, R. Luo, H. Zhu, Bilkent University, C. Alkan, E. Dal, F. Kahveci, Boston 649 College, G.T. Marth, E.P. Garrison, D. Kural, W.-P. Lee, A.N. Ward, J. Wu, M. Zhang, Broad Institute of MIT and Harvard, S.A. McCarroll, R.E. Handsaker, D.M. Altshuler, E. Banks, G. 650 651 Del Angel, G. Genovese, C. Hartl, H. Li, S. Kashin, J.C. Nemesh, K. Shakir, Cold Spring 652 Harbor Laboratory, S.C. Yoon, J. Lihm, V. Makarov, Cornell University, J. Degenhardt, 653 European Molecular Biology Laboratory, J.O. Korbel, M.H. Fritz, S. Meiers, B. Raeder, T. 654 Rausch, A.M. Stütz, European Molecular Biology Laboratory, European Bioinformatics 655 Institute, P. Flicek, F. Paolo Casale, L. Clarke, R.E. Smith, O. Stegle, X. Zheng-Bradley, 656 Illumina, D.R. Bentley, B. Barnes, R. Keira Cheetham, M. Eberle, S. Humphray, S. Kahn, L. 657 Murray, R. Shaw, Leiden University Medical Center, E.-W. Lameijer, Louisiana State 658 University, M.A. Batzer, M.K. Konkel, J.A. Walker, McDonnell Genome Institute at 659 Washington University, L. Ding, I. Hall, K. Ye, Stanford University, P. Lacroute, The Jackson 660 Laboratory for Genomic Medicine, C. Lee, E. Cerveira, A. Malhotra, J. Hwang, D. Plewczynski, K. Radew, M. Romanovitch, C. Zhang, Translational Genomics Research 661 662 Institute, D.W. Craig, N. Homer, US National Institutes of Health, D. Church, C. Xiao, 663 University of California, San Diego, J. Sebat, D. Antaki, V. Bafna, J. Michaelson, K. Ye, 664 University of Maryland School of Medicine, S.E. Devine, E.J. Gardner, University of Michigan, 665 G.R. Abecasis, J.M. Kidd, R.E. Mills, G. Dayama, S. Emery, G. Jun, University of North 666 Carolina at Charlotte, X. Shi, A. Quitadamo, University of Oxford, G. Lunter, G.A. McVean, 667 University of Texas MD Anderson Cancer Center, K. Chen, X. Fan, Z. Chong, T. Chen, 668 University of Utah, D. Witherspoon, J. Xing, University of Washington, E.E. Eichler, M.J. 669 Chaisson, F. Hormozdiari, J. Huddleston, M. Malig, B.J. Nelson, P.H. Sudmant, Vanderbilt 670 University School of Medicine, N.F. Parrish, Weill Cornell Medical College, E. Khurana, Wellcome Trust Sanger Institute, M.E. Hurles, B. Blackburne, S.J. Lindsay, Z. Ning, K. Walter, 671 672 Y. Zhang, Yale University, M.B. Gerstein, A. Abyzov, J. Chen, D. Clarke, H. Lam, X. Jasmine Mu, C. Sisu, J. Zhang, Y. Zhang, Exome group, Baylor College of Medicine, R.A. Gibbs, F. 673 674 Yu, M. Bainbridge, D. Challis, U.S. Evani, C. Kovar, J. Lu, D. Muzny, U. Nagaswamy, J.G. 675 Reid, A. Sabo, J. Yu, BGI-Shenzhen, X. Guo, W. Li, Y. Li, R. Wu, Boston College, G.T. Marth, 676 E.P. Garrison, W. Fung Leong, A.N. Ward, Broad Institute of MIT and Harvard, G. Del Angel, 677 M.A. DePristo, S.B. Gabriel, N. Gupta, C. Hartl, R.E. Poplin, Cornell University, A.G. Clark, 678 J.L. Rodriguez-Flores, European Molecular Biology Laboratory, European Bioinformatics 679 Institute, P. Flicek, L. Clarke, R.E. Smith, X. Zheng-Bradley, Massachusetts General Hospital, 680 D.G. MacArthur, McDonnell Genome Institute at Washington University, E.R. Mardis, R.

682

683

684

685 686

687

688

689 690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710

711

712

713

714

715

716

717

718

719

720

721

722723

724

725

726

727

728 729 Fulton, D.C. Koboldt, McGill University, S. Gravel, Stanford University, C.D. Bustamante, Translational Genomics Research Institute, D.W. Craig, A. Christoforides, N. Homer, T. Izatt, US National Institutes of Health, S.T. Sherry, C. Xiao, University of Geneva, E.T. Dermitzakis, University of Michigan, G.R. Abecasis, H. Min Kang, University of Oxford, G.A. McVean, Yale University, M.B. Gerstein, S. Balasubramanian, L. Habegger, Functional interpretation group, Cornell University, H. Yu, European Molecular Biology Laboratory, European Bioinformatics Institute, P. Flicek, L. Clarke, F. Cunningham, I. Dunham, D. Zerbino, X. Zheng-Bradley, Harvard University, K. Lage, J. Berg Jespersen, H. Horn, Stanford University, S.B. Montgomery, M.K. DeGorter, Weill Cornell Medical College, E. Khurana, Wellcome Trust Sanger Institute, C. Tyler-Smith, Y. Chen, V. Colonna, Y. Xue, Yale University, M.B. Gerstein, S. Balasubramanian, Y. Fu, D. Kim, Chromosome Y group, Albert Einstein College of Medicine, A. Auton, A. Marcketta, American Museum of Natural History, R. Desalle, A. Narechania, Arizona State University, M.A. Wilson Sayres, Boston College, E.P. Garrison, Broad Institute of MIT and Harvard, R.E. Handsaker, S. Kashin, S.A. McCarroll, Cornell University, J.L. Rodriguez-Flores, European Molecular Biology Laboratory, European Bioinformatics Institute, P. Flicek, L. Clarke, X. Zheng-Bradley, New York Genome Center, Y. Erlich, M. Gymrek, T. Frederick Willems, Stanford University, C.D. Bustamante, F.L. Mendez, G. David Poznik, P.A. Underhill, The Jackson Laboratory for Genomic Medicine, C. Lee, E. Cerveira, A. Malhotra, M. Romanovitch, C. Zhang, University of Michigan, G.R. Abecasis, University of Queensland, L. Coin, H. Shao, Virginia Bioinformatics Institute, D. Mittelman, Wellcome Trust Sanger Institute, C. Tyler-Smith, Q. Ayub, R. Banerjee, M. Cerezo, Y. Chen, T.W. Fitzgerald, S. Louzada, A. Massaia, S. McCarthy, G.R. Ritchie, Y. Xue, F. Yang, Data coordination center group, Baylor College of Medicine, R.A. Gibbs, C. Kovar, D. Kalra, W. Hale, D. Muzny, J.G. Reid, BGI-Shenzhen, J. Wang, X. Dan, X. Guo, G. Li, Y. Li, C. Ye, X. Zheng, Broad Institute of MIT and Harvard, D.M. Altshuler, European Molecular Biology Laboratory, European Bioinformatics Institute, P. Flicek, L. Clarke, X. Zheng-Bradley, Illumina, D.R. Bentley, A. Cox, S. Humphray, S. Kahn, Max Planck Institute for Molecular Genetics, R. Sudbrak, M.W. Albrecht, M. Lienhard, McDonnell Genome Institute at Washington University, D. Larson, Translational Genomics Research Institute, D.W. Craig, T. Izatt, A.A. Kurdoglu, US National Institutes of Health, S.T. Sherry, C. Xiao, University of California, Santa Cruz, D. Haussler, University of Michigan, G.R. Abecasis, University of Oxford, G.A. McVean, Wellcome Trust Sanger Institute, R.M. Durbin, S. Balasubramaniam, T.M. Keane, S. McCarthy, J. Stalker, Samples and ELSI group, A. Chakravarti, B.M. Knoppers, G.R. Abecasis, K.C. Barnes, C. Beiswanger, E.G. Burchard, C.D. Bustamante, H. Cai, H. Cao, R.M. Durbin, N.P. Gerry, N. Gharani, R.A. Gibbs, C.R. Gignoux, S. Gravel, B. Henn, D. Jones, L. Jorde, J.S. Kaye, A. Keinan, A. Kent, A. Kerasidou, Y. Li, R. Mathias, G.A. McVean, A. Moreno-Estrada, P.N. Ossorio, M. Parker, A.M. Resch, C.N. Rotimi, C.D. Royal, K. Sandoval, Y. Su, R. Sudbrak, Z. Tian, S. Tishkoff, L.H. Toji, C. Tyler-Smith, M. Via, Y. Wang, H. Yang, L. Yang, J. Zhu, Sample collection, British from England and Scotland (GBR), W. Bodmer, Colombians in Medellín, Colombia (CLM), G. Bedoya, A. Ruiz-Linares, Han Chinese South (CHS), Z. Cai, Y. Gao, J. Chu, Finnish in Finland (FIN), L. Peltonen, Iberian Populations in Spain (IBS), A. Garcia-Montero, A. Orfao, Puerto Ricans in Puerto Rico (PUR), J. Dutil, J.C. Martinez-Cruzado, T.K. Oleksyk, African Caribbean in Barbados (ACB), K.C. Barnes, R.A. Mathias, A. Hennis, H. Watson, C. McKenzie, Bengali in Bangladesh (BEB), F. Qadri, R. LaRocque, P.C. Sabeti, Chinese Dai in Xishuangbanna, China (CDX), J. Zhu, X. Deng, Esan in Nigeria (ESN), P.C. Sabeti, D. Asogun, O. Folarin, C. Happi, O. Omoniwa, M. Stremlau, R. Tariyal, Gambian in Western Division – Mandinka (GWD), M. Jallow, F. Sisay Joof, T. Corrah, K. Rockett, D. Kwiatkowski, Indian Telugu in the UK (ITU) and Sri Lankan Tamil in the UK (STU), J. Kooner, Kinh in Ho Chi Minh City, Vietnam (KHV), T. Tinh Hiê'n, S.J. Dunstan, N.

- Thuy Hang, Mende in Sierra Leone (MSL), R. Fonnie, R. Garry, L. Kanneh, L. Moses, P.C.
- Sabeti, J. Schieffelin, D.S. Grant, Peruvian in Lima, Peru (PEL), C. Gallo, G. Poletti, Punjabi in
- Lahore, Pakistan (PJL), D. Saleheen, A. Rasheed, Scientific management, L.D. Brooks, A.L.
- Felsenfeld, J.E. McEwen, Y. Vaydylevich, E.D. Green, A. Duncanson, M. Dunn, J.A. Schloss,
- J. Wang, H. Yang, Writing group, A. Auton, L.D. Brooks, R.M. Durbin, E.P. Garrison, H. Min
- Kang, J.O. Korbel, J.L. Marchini, S. McCarthy, G.A. McVean, G.R. Abecasis, A global
- reference for human genetic variation, Nature 526 (2015) 68–74.
- 737 https://doi.org/10.1038/nature15393.
- 738 [22] A. Gusev, A. Ko, H. Shi, G. Bhatia, W. Chung, B.W.J.H. Penninx, R. Jansen, E.J.C. de Geus,
- D.I. Boomsma, F.A. Wright, P.F. Sullivan, E. Nikkola, M. Alvarez, M. Civelek, A.J. Lusis, T.
- Lehtimäki, E. Raitoharju, M. Kähönen, I. Seppälä, O.T. Raitakari, J. Kuusisto, M. Laakso, A.L.
- Price, P. Pajukanta, B. Pasaniuc, Integrative approaches for large-scale transcriptome-wide
- association studies, Nat Genet 48 (2016) 245–252. https://doi.org/10.1038/ng.3506.
- 743 [23] Y. Hu, M. Li, Q. Lu, H. Weng, J. Wang, S.M. Zekavat, Z. Yu, B. Li, J. Gu, S. Muchnik, Y. Shi,
- B.W. Kunkle, S. Mukherjee, P. Natarajan, A. Naj, A. Kuzma, Y. Zhao, P.K. Crane, H. Lu, H.
- Zhao, A statistical framework for cross-tissue transcriptome-wide association analysis, Nat
- 746 Genet 51 (2019) 568–576. https://doi.org/10.1038/s41588-019-0345-7.
- 747 [24] G. Hemani, J. Zheng, B. Elsworth, K.H. Wade, V. Haberland, D. Baird, C. Laurin, S. Burgess,
- J. Bowden, R. Langdon, V.Y. Tan, J. Yarmolinsky, H.A. Shihab, N.J. Timpson, D.M. Evans, C.
- Relton, R.M. Martin, G. Davey Smith, T.R. Gaunt, P.C. Haycock, The MR-Base platform
- supports systematic causal inference across the human phenome, eLife 7 (2018) e34408.
- 751 https://doi.org/10.7554/eLife.34408.
- 752 [25] C. Giambartolomei, D. Vukcevic, E.E. Schadt, L. Franke, A.D. Hingorani, C. Wallace, V.
- Plagnol, Bayesian test for colocalisation between pairs of genetic association studies using
- summary statistics, PLoS Genetics 10 (2014) e1004383.
- 755 https://doi.org/10.1371/journal.pgen.1004383.
- 756 [26] J. Zhu, C. Ma, L. Zhu, J. Li, F. Peng, L. Huang, X. Luan, A role for the NLRC4 inflammasome
- in premature rupture of membrane, PLoS ONE 15 (2020) e0237847.
- 758 https://doi.org/10.1371/journal.pone.0237847.
- 759 [27] D. Zheng, T. Liwinski, E. Elinav, Inflammasome activation and regulation: toward a better
- understanding of complex mechanisms, Cell Discov 6 (2020) 36.
- 761 https://doi.org/10.1038/s41421-020-0167-x.
- 762 [28] Y. An, Z. Zhai, X. Wang, Y. Ding, L. He, L. Li, Q. Mo, C. Mu, R. Xie, T. Liu, W. Zhong, B.
- Wang, H. Cao, Targeting Desulfovibrio vulgaris flagellin-induced NAIP/NLRC4
- 764 inflammasome activation in macrophages attenuates ulcerative colitis, Journal of Advanced
- 765 Research 52 (2023) 219–232. https://doi.org/10.1016/j.jare.2023.08.008.
- 766 [29] J. Sim, J.W. Ahn, J. Park, Y.J. Kim, J.-Y. Jeong, J.M. Lee, K. Cho, H.J. Ahn, K.S. Sung, J.-S.
- Moon, J.H. Moon, J. Lim, Non-canonical NLRC4 inflammasomes in astrocytes contribute to
- 768 glioma malignancy, Inflamm. Res. 72 (2023) 813–827. https://doi.org/10.1007/s00011-023-
- 769 01710-6.

- 770 [30] C. Delgado-Arévalo, M. Calvet-Mirabent, A. Triguero-Martínez, E. Vázquez De Luis, A.
- Benguría-Filippini, R. Largo, D. Calzada-Fraile, O. Popova, I. Sánchez-Cerrillo, I. Tsukalov, R.
- Moreno-Vellisca, H. De La Fuente, G. Herrero-Beaumont, A. Ramiro, F. Sánchez-Madrid, S.
- Castañeda, A. Dopazo, I. González Álvaro, E. Martin-Gayo, NLRC4-mediated activation of
- 774 CD1c+ DC contributes to perpetuation of synovitis in rheumatoid arthritis, JCI Insight 7 (2022)
- 775 e152886. https://doi.org/10.1172/jci.insight.152886.
- 776 [31] R.E. Vance, The NAIP/NLRC4 inflammasomes, Current Opinion in Immunology 32 (2015) 84–89. https://doi.org/10.1016/j.coi.2015.01.010.
- 778 [32] W. Deng, L. Wang, Y. Xiong, J. Li, Y. Wang, T. Shi, D. Ma, The novel secretory protein
- 779 CGREF1 inhibits the activation of AP-1 transcriptional activity and cell proliferation, The
- 780 International Journal of Biochemistry & Cell Biology 65 (2015) 32–39.
- 781 https://doi.org/10.1016/j.biocel.2015.05.019.
- 782 [33] M. Xiang, Y. Gao, Y. Zhou, M. Wang, X. Yao, A novel nomogram based on cell cycle-related
- genes for predicting overall survival in early-onset colorectal cancer, BMC Cancer 23 (2023)
- 784 595. https://doi.org/10.1186/s12885-023-11075-y.
- 785 [34] M. Xie, H. Dai, Q. Gu, C. Xiao, H. Wang, Y. Lei, C. Wu, X. Li, B. Lin, S. Li, Identification of
- genes contributing to cisplatin resistance in osteosarcoma cells, FEBS Open Bio 13 (2023) 164–
- 787 173. https://doi.org/10.1002/2211-5463.13524.
- 788 [35] M.T. Le, M.A. Lanaspa, C.M. Cicerchi, J. Rana, J.D. Scholten, B.L. Hunter, C.J. Rivard, R.K.
- Randolph, R.J. Johnson, Bioactivity-Guided Identification of Botanical Inhibitors of
- 790 Ketohexokinase, PLoS ONE 11 (2016) e0157458.
- 791 https://doi.org/10.1371/journal.pone.0157458.
- 792 [36] J. Kim, J. Kang, Y.-L. Kang, J. Woo, Y. Kim, J. Huh, J.-W. Park, Ketohexokinase-A acts as a
- nuclear protein kinase that mediates fructose-induced metastasis in breast cancer, Nat Commun
- 794 11 (2020) 5436. https://doi.org/10.1038/s41467-020-19263-1.
- 795 [37] X. Li, X. Qian, L.-X. Peng, Y. Jiang, D.H. Hawke, Y. Zheng, Y. Xia, J.-H. Lee, G. Cote, H.
- Wang, L. Wang, C.-N. Qian, Z. Lu, A splicing switch from ketohexokinase-C to
- ketohexokinase-A drives hepatocellular carcinoma formation, Nat Cell Biol 18 (2016) 561–571.
- 798 https://doi.org/10.1038/ncb3338.
- 799 [38] J. Yang, S. Yang, Q. Wang, J. Pang, Y. Wang, H. Wang, X. Fu, KHK-A promotes the
- proliferation of oesophageal squamous cell carcinoma through the up-regulation of PRPS1,
- Arab Journal of Gastroenterology 22 (2021) 40–46. https://doi.org/10.1016/j.ajg.2020.08.007.
- 802 [39] J.A. Johnston, D.R. Nelson, P. Bhatnagar, S.E. Curtis, Y. Chen, J.G. MacKrell, Prevalence and
- cardiometabolic correlates of ketohexokinase gene variants among UK Biobank participants,
- PLoS ONE 16 (2021) e0247683. https://doi.org/10.1371/journal.pone.0247683.
- 805 [40] C.-H. Yu, T. Xie, R.-P. Zhang, Z.-C. A, Association of the common SNPs in RNF212, STAG3
- and RFX2 gene with male infertility with azoospermia in Chinese population, European Journal
- of Obstetrics & Gynecology and Reproductive Biology 221 (2018) 109–112.
- 808 https://doi.org/10.1016/j.ejogrb.2017.12.030.

- 809 [41] A. Riera-Escamilla, A. Enguita-Marruedo, D. Moreno-Mendoza, C. Chianese, E. Sleddens-810 Linkels, E. Contini, M. Benelli, A. Natali, G.M. Colpi, E. Ruiz-Castañé, M. Maggi, W.M.
- Baarends, C. Krausz, Sequencing of a 'mouse azoospermia' gene panel in azoospermic men:
- identification of RNF212 and STAG3 mutations as novel genetic causes of meiotic arrest,
- Human Reproduction 34 (2019) 978–988. https://doi.org/10.1093/humrep/dez042.
- [42] A. Reynolds, H. Qiao, Y. Yang, J.K. Chen, N. Jackson, K. Biswas, J.K. Holloway, F. Baudat, B.
 De Massy, J. Wang, C. Höög, P.E. Cohen, N. Hunter, RNF212 is a dosage-sensitive regulator of crossing-over during mammalian meiosis, Nat Genet 45 (2013) 269–278.
 https://doi.org/10.1038/ng.2541.
- [43] Y. Fujiwara, H. Matsumoto, K. Akiyama, A. Srivastava, M. Chikushi, M. Ann Handel, T.
 Kunieda, An ENU-induced mutation in the mouse Rnf212 gene is associated with male meiotic failure and infertility, REPRODUCTION 149 (2015) 67–74. https://doi.org/10.1530/REP-14-0122.
- [44] H. Qiao, H.B.D. Prasada Rao, Y. Yang, J.H. Fong, J.M. Cloutier, D.C. Deacon, K.E. Nagel,
 R.K. Swartz, E. Strong, J.K. Holloway, P.E. Cohen, J. Schimenti, J. Ward, N. Hunter,
 Antagonistic roles of ubiquitin ligase HEI10 and SUMO ligase RNF212 regulate meiotic
 recombination, Nat Genet 46 (2014) 194–199. https://doi.org/10.1038/ng.2858.

9 Tables

826

827

828

9.1 Table 1

Gene	C h	Position	Z_TWA S	P_TW AS	P_TWAS (FDR)	Tissue	topSNP	B_SM R	SE_S MR	P_SM R	P_SMR (FDR)	P_HEI DI	N_HEI DI
NLRC 4	2	322658 53	-5.33	9.8E- 08	5.1E-05	GTExv8.Whole_BI	rs38507 6	-0.13	0.02	7.9E- 09	9.5E-06	3.6E- 01	20
CGRE F1	2	271191 14	-4.76	1.9E- 06	5.0E-04	GTExv8.Whole_Bl	rs23046 81	-0.38	0.09	2.1E- 05	4.6E-03	4.4E- 01	20
КНК	2	270867 46	-4.73	2.3E- 06	5.7E-04	GTExv8.Whole_Bl	rs21190 26	-0.06	0.01	2.3E- 06	1.0E-03	2.5E- 01	20
RNF2 12	4	111356 1	3.75	1.8E- 04	0.01	GTExv8.Whole_Bl	rs49745 91	0.19	0.04	1.2E- 07	9.4E-05	5.5E- 02	20

- 829 Table 1 TWAS / SMR/HEIDI results of the GWAS data on Dorsopathies, blood eQTL
- data.TWAS/SMR/HEIDI results of the GWAS data on Dorsopathies, blood eOTL data. Ch
- represents chromosome; position indicates the gene's position, Z_TWAS, P_TWAS are the Z-score
- and p-value of the TWAS test; Tissue represents the tissue source used in the TWAS analyses.
- topSNP represents the top SNP in the SMR analyses. P_SMR is the p-value for the SMR test;
- B SMR is the effect size from the SMR test; SE SMR is the standard error of B SMR; P HEIDI is

the p-value for the HEIDI test; N_HEIDI is the number of SNPs used in the HEIDI test; FDR represents false discovery rate.

9.2 Table 2

Marker	Gene	Methylation on Gene		Methylation on Dorsopathies			Gene on Dorsopathies			Intermediary analyses			prop mediate d	prop mediated se	
		b	se	р	b	se	р	b	se	р	indirect	indirect_se	indirect_p	-	
cg0468695 3	RNF21 2	0.5	0.0 7	2.08E -14	-0.1	0.0	2.68E -06	0.1 9	0.0	1.20E -07	-0.1	0.02	1.35E-05	93.79%	0.29
cg2663850 5	NLRC4	0.8	0.1	1.25E -09	0.0	0.0	1.43E -03	0.1	0.0	7.87E -09	0.11	0.03	2.87E-05	120.00 %	0.47
cg 1894812 5	NLRC4	0.9	0.1 7	1.72E -08	0.1	0.0	5.59E -04	0.1	0.0	7.87E -09	0.12	0.03	5.50E-05	104.41 %	0.4
cg2274078 3	CGRE F1	0.3	0.0 6	7.71E -07	- 0.1 3	0.0	1.63E -04	0.3	0.0 9	2.12E -05	-0.12	0.04	1.27E-03	92.24%	0.38
cg0611241 5	CGRE F1	0.3	0.0 7	1.75E -06	0.1	0.0	5.59E -04	- 0.3 8	0.0 9	2.12E -05	0.13	0.04	1.49E-03	110.63 %	0.47

Table 2 Main Results of Intermediary analyses. b is the effect size, se is the standard error of effect size, and p is the P-value. prop_mediated represents the proportion of indirect effect in the total effect.

10 Figures

10.1 Figure 1





Fig.1 Venn Plot of the main results of multi analysis

10.2 Figure 2



- Fig.2 Methylation sites affect disease pathways.
- 852 **10.3 Figure 3**




Fig.3 Manhattan plot of the MR/SMR/FUSION analysis results using QTLs and Dorsopathies GWAS summary statistics. The red dashed line represents the Bonferroni-corrected significance threshold.

10.4 Figure 4

Gene	method	nSNP		pval	OR (95% CI)
NLRC4	Inverse variance weighted	21	• [1.09e-11	0.886 (0.855 - 0.917)
CGREF1	Wald ratio	1	- :	8.74e-07	0.682 (0.585 - 0.794)
KHK	Inverse variance weighted	32	• ;	3.67e-16	0.936 (0.921 - 0.951)
RNF212	Inverse variance weighted	11	-	1.01e-03	1.145 (1.056 - 1.241)
		0	1	2	

Fig.4 MR results for genes expression significantly associated with dorsopathies after FDR correction.

10.5 Figure 5




Fig. 5 SMR locus plot illustrating dorsopathies at the gene locus utilizing blood eQTL data. In the upper plot, each gray dot represents a SNP identified through GWAS on dorsopathies. A red diamond indicates passage of the SMR test for the probe, while a solid diamond signifies successful completion of both the SMR and HEIDI tests. In the lower plot, each red cross represents an SNP identified in the eQTL study corresponding to each gene. The x-axis displays the genomic positions (Mb, GRCh37) of SNPs, probes, and genes on the chromosome. The y-axis displays the negative logarithm (base 10) of p-values for SNPs identified in the GWAS on dorsopathies, SMR test, and eQTL study corresponding to each gene.

10.6 Figure 6




Fig. 6 Locus comparison plot displays the results of colocalization analysis for SNPs associated with gene expression in blood and datasets related to dorsopathies. Each dot represents a specific SNP, with the color indicating its linkage disequilibrium (LD) value (r2) with the lead GWAS variant, marked by a purple diamond. In the right panel, the x-axis represents genomic positions in megabases (GRCh37) along the chromosome, while the y-axis shows the -log10 p-values for SNPs from the dorsopathies GWAS (top) and the gene expression eQTL study (bottom). The left panel compares the p-values from the dorsopathies GWAS with those from the gene expression eQTL study.